{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:59:19Z","timestamp":1791932359744,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN272201700077C"],"award-info":[{"award-number":["HHSN272201700077C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.vaccine.2025.127137","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T03:09:47Z","timestamp":1747105787000},"page":"127137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A Brighton Collaboration standardized template with key considerations for a benefit\/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever"],"prefix":"10.1016","volume":"58","author":[{"given":"Kevin","family":"Spurgers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Wynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovelyn","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrius","family":"Matassov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Gerardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Gurwith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127137_bb0005","unstructured":"(PHAC), P. H. (2012,112). Pathogen Safety Data Sheets: Infectious Substances \u2013 Vesicular stomatitis virus (VSV). Retrieved 8 20, 2020, from https:\/\/www.canada.ca\/en\/publichealth\/ services\/laboratory-biosafety-biosecurity\/pathogen-safety-data-sheets-riskassessment\/ vesicular-stomatitis-virus.html."},{"issue":"2","key":"10.1016\/j.vaccine.2025.127137_bb0010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0042-6822(89)90287-0","article-title":"Nucleotide sequence of the Lassa virus (Josiah strain) S genome RNA and amino acid sequence comparison of the N and GPC proteins to other arenaviruses","volume":"168","author":"Auperin","year":"1989","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2025.127137_bb0015","unstructured":"Bioinformatics, S. I. (2020). Esiculovirus Swiss Institute of Bioinformatics (SIB). Retrieved 9 29, from https:\/\/viralzone.expasy.org\/21?outline=all_by_species."},{"key":"10.1016\/j.vaccine.2025.127137_bb0020","series-title":"The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI)","first-page":"298","volume":"21(3\u20134)","author":"Bonhoeffer","year":"2002"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127137_bb0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2105\/AJPH.47.2.205","article-title":"Epizootiology of vesicular stomatitis","volume":"47","author":"Brandly","year":"1957","journal-title":"Am J Public Health Nations Health"},{"key":"10.1016\/j.vaccine.2025.127137_bb0030","unstructured":"CDC. (2019, 1 31). Lassa Fever: Centers for Disease Contol and Prevention (United States of America). Retrieved 8 20, 2020, from https:\/\/www.cdc.gov\/vhf\/lassa\/index.html."},{"key":"10.1016\/j.vaccine.2025.127137_bb0035","author":"CDC, A"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127137_bb0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.vaccine.2014.09.035","article-title":"The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)","volume":"33","author":"Chen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127137_bb0045","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1016\/j.vaccine.2016.06.071","article-title":"ive virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk\/benefit assessment","volume":"34","author":"Clarke","year":"2016","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127137_bb0050","doi-asserted-by":"crossref","first-page":"875","DOI":"10.4269\/ajtmh.1976.25.875","article-title":"Ecological associations of vesicular stomatitis virus in rural Central America and Panama","volume":"25","author":"Cline","year":"1976","journal-title":"Am J Trop Med hyg"},{"issue":"49","key":"10.1016\/j.vaccine.2025.127137_bb0055","doi-asserted-by":"crossref","first-page":"7708","DOI":"10.1016\/j.vaccine.2020.08.009","article-title":"The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines","volume":"38","author":"Condit","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127137_bb0060","author":"Consortium, V. H"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127137_bb0065","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/JVI.01515-07","article-title":"Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice","volume":"82","author":"Cooper","year":"2008","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127137_bb0070","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1172\/JCI131958","article-title":"Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death","volume":"130","author":"Cross","year":"2020","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127137_bb0075","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/0300-1652.132037","article-title":"Acute abdominal pain in patients with lassa fever: Radiological assessment and diagnostic challenges","volume":"55","author":"Eze","year":"2014","journal-title":"Niger Med J"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127137_bb0080","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41579-022-00789-8","article-title":"Lassa fever - the road ahead","volume":"21","author":"Garry","year":"2023","journal-title":"Nat Rev Microbiol"},{"issue":"j2986","key":"10.1016\/j.vaccine.2025.127137_bb0085","article-title":"Lassa fever","volume":"358","author":"Houlihan","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127137_bb0090","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/104063879700900205","article-title":"Experimental vesicular stomatitis in swine: effects of route of inoculation and steroid treatment","volume":"9","author":"Howerth","year":"1997","journal-title":"J Vet Diagn Invest"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127137_bb0095","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1073\/pnas.92.10.4477","article-title":"Recombinant vesicular stomatitis viruses from DNA","volume":"92","author":"Lawson","year":"1995","journal-title":"PNAS"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127137_bb0100","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/tvjl.1998.0303","article-title":"Vesicular stomatitis","volume":"157","author":"Letchworth","year":"1999","journal-title":"Vet J"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127137_bb0105","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.molmed.2004.03.003","article-title":"Vesicular stomatitis virus: re-inventing the bullet","volume":"10","author":"Lichty","year":"2004","journal-title":"Trends Mol Med"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127137_bb0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/pathogens8010017","article-title":"Virus\u2013Host Interactions Involved in Lassa Virus Entry and Genome Replication","volume":"8","author":"Loureiro","year":"2019","journal-title":"Pathogens"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127137_bb0115","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3390\/vaccines12080858","article-title":"Preclinical Safety Assessment of the EBS-LASV Vaccine Candidate against Lassa Fever Virus","volume":"12","author":"Matassov","year":"2024","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127137_bb0120","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/infdis\/155.3.445","article-title":"A case-control study of the clinical diagnosis and course of Lassa fever","volume":"155","author":"McCormick","year":"1987","journal-title":"J Infect Dis"},{"issue":"5452","key":"10.1016\/j.vaccine.2025.127137_bb0125","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1126\/science.287.5452.485","article-title":"Transmission of vesicular stomatitis virus from infected to noninfected black flies co-feeding on nonviremic deer mice","volume":"287","author":"Mead","year":"2000","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127137_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009788","article-title":"Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design","volume":"15","author":"Merson","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"100009","key":"10.1016\/j.vaccine.2025.127137_bb0135","article-title":"rVSV\u0394G-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk\/benefit assessment","volume":"1","author":"Monath","year":"2019","journal-title":"Vaccine X"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127137_bb0140","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4269\/ajtmh.1987.36.408","article-title":"Pediatric Lassa fever: a review of 33 Liberian cases","volume":"36","author":"Monson","year":"1987","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.127137_bb0145","article-title":"Arenaviruses. I. The epidemiology molecular and cell biology of arenaviruses. Introduction","volume":"262","author":"Oldstone","year":"2002","journal-title":"Curr Top Microbiol Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127137_bb0150","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nri.2016.138","article-title":"Immunobiology of Ebola and Lassa virus infections","volume":"17","author":"Prescott","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127137_bb0155","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1099\/jgv.0.001280","article-title":"ICTV Virus Taxonomy Profile: Arenaviridae","volume":"100","author":"Radoshitzky","year":"2019","journal-title":"J Gen Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127137_bb0160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4269\/ajtmh.1987.36.177","article-title":"Epizootic vesicular stomatitis in Colorado, 1982: infection in occupational risk groups","volume":"36","author":"Reif","year":"1987","journal-title":"Am J Trop Med Hyg"},{"issue":"7426","key":"10.1016\/j.vaccine.2025.127137_bb0165","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/bmj.327.7426.1271","article-title":"Lassa fever: epidemiology, clinical features, and social consequences","volume":"327","author":"Richmond","year":"2003","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127137_bb0170","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/oxfordjournals.aje.a121284","article-title":"Vesicular stomatitis virus, Indiana serotype: multiplication in and transmission by experimentally infected phlebotomine sandflies (Lutzomyia trapidoi)","volume":"93","author":"Tesh","year":"1971","journal-title":"Am J Epidemiol"},{"issue":"4029","key":"10.1016\/j.vaccine.2025.127137_bb0175","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1126\/science.175.4029.1477","article-title":"Vesicular stomatitis virus (Indiana serotype): transovarial transmission by phlebotomine sandlies","volume":"175","author":"Tesh","year":"1972","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127137_bb0180","doi-asserted-by":"crossref","first-page":"S1090","DOI":"10.1093\/infdis\/jir379","article-title":"Protective Efficacy of a Bivalent Recombinant Vesicular Stomatitis Virus Vaccine in the Syrian Hamster Model of Lethal Ebola Virus Infection","volume":"204","author":"Tsuda","year":"2011","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127137_bb0185","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4269\/ajtmh.1987.36.183","article-title":"Epizootic vesicular stomatitis in Colorado, 1982: epidemiologic studies along the northern Colorado front range","volume":"36","author":"Webb","year":"1987","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.127137_bb0190","unstructured":"WHO. (2017). Lassa Fever World Health Organization 2017. Retrieved 8 20, 2020, from https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lassafever."},{"key":"10.1016\/j.vaccine.2025.127137_bb0195","author":"WHO"},{"key":"10.1016\/j.vaccine.2025.127137_bb0200","series-title":"Weekly Epidemiological Record No. 28. Online Print","first-page":"310","volume":"94","author":"WHO","year":"2019"},{"key":"10.1016\/j.vaccine.2025.127137_bb0205","series-title":"Weekly Epidemiological Record. No. 4. Online Print","first-page":"29","volume":"95","author":"WHO","year":"2020"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127137_bb0210","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jviromet.2006.02.006","article-title":"An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development","volume":"135","author":"Witko","year":"2006","journal-title":"J Virol Methods"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127137_bb0215","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1099\/vir.0.065201-0","article-title":"Pseudotyping of vesicular stomatitis virus with the envelope glycoproteins of highly pathogenic avian influenza viruses","volume":"95","author":"Zimmer","year":"2014","journal-title":"J Gen Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25004347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25004347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T10:52:47Z","timestamp":1749034367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25004347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":43,"alternative-id":["S0264410X25004347"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127137","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Brighton Collaboration standardized template with key considerations for a benefit\/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127137"}}